Concepedia

Stephen W. Kaldor

SW

Statistics

Publications

31

Citations

3.2K

H-Index

23

Active since

1990

Affiliations

Eli Lilly (United States)(Current)

General Atomics (United States)

University of Chicago

Stephen W. Kaldor is an author at Eli Lilly (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

1990–2024

31

Publications

31

Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Stephen W. Kaldor, Vincent J. Kalish, Jay F. Davies et al. · Journal of Medicinal Chemistry · 1997 · 620 citations · Full text

, , +17

Discovery of Alogliptin:  A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV

Jun Feng, Zhiyuan Zhang, Michael B. Wallace et al. · Journal of Medicinal Chemistry · 2007 · 404 citations · Full text

, , +6

Total synthesis of the macrolide antibiotic cytovaricin

David A. Evans, Stephen W. Kaldor, Todd K. Jones et al. · Journal of the American Chemical Society · 1990 · 312 citations

, , +9

Use of solid supported nucleophiles and electrophiles for the purification of non-peptide small molecule libraries

Stephen W. Kaldor, Miles G. Siegel, James E. Fritz et al. · Tetrahedron Letters · 1996 · 227 citations

, , +8

Solid phase synthesis of hydantoins using a carbamate linker and a novel cyclization / cleavage step

Bruce A. Dressman, Larry A. Spangle, Stephen W. Kaldor · Tetrahedron Letters · 1996 · 209 citations

, , +8

1–5 of 31